Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis

S. T. Choi, J. H. Kim, E. J. Kang, S. W. Lee, M. C. Park, YongBeom Park, S. K. Lee

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Objectives. To determine whether osteopontin (OPN) is increased in patients with AS and to investigate its relationship to inflammatory disease activity and bone remodelling process. Methods. This cross-sectional study included 30 patients with AS and 23 age- and sex-matched healthy controls. We assessed clinical characteristics and laboratory parameters including the ESR, CRP, lipid profiles, the Bath AS disease activity index (BASDAI) and the Bath AS radiographic index (BASRI). To evaluate bone metabolism, we tested ALP, OCN and C-telopeptide of type I collagen (CTX-I). Plasma levels of OPN, TNF-α and IL-6 were measured by ELISA, and mRNA expression in peripheral blood mononuclear cells (PBMCs) was performed by RT-PCR. Changes in OPN level were also evaluated in eight patients after the treatment with a TNF-α blocker. Results. Patients with AS had significantly higher plasma OPN, TNF-α and IL-6 levels and more mRNA expression than healthy controls. Plasma OPN levels were correlated with serum ALP, OCN and CTX-I levels, but not with ESR, CRP, lipid profiles, BASDAI or BASRI. Treatment with a TNF-α blocker did not alter OPN levels, although it reduced the disease activity. Conclusions. Patients with AS had higher levels of OPN compared with controls. The plasma OPN level was correlated with serum ALP, OCN and CTX-I levels, but not with disease activity in AS. OPN might be involved in bone remodelling rather than in inflammation in AS.

Original languageEnglish
Pages (from-to)1775-1779
Number of pages5
JournalRheumatology
Volume47
Issue number12
DOIs
Publication statusPublished - 2008 Nov 28

Fingerprint

Osteopontin
Bone Remodeling
Ankylosing Spondylitis
Inflammation
Baths
Interleukin-6
Lipids
Messenger RNA
Collagen Type I
Serum
Blood Cells
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay
Bone and Bones
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Pharmacology (medical)

Cite this

Choi, S. T. ; Kim, J. H. ; Kang, E. J. ; Lee, S. W. ; Park, M. C. ; Park, YongBeom ; Lee, S. K. / Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. In: Rheumatology. 2008 ; Vol. 47, No. 12. pp. 1775-1779.
@article{91602a6fccd64475bf8be96038389de9,
title = "Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis",
abstract = "Objectives. To determine whether osteopontin (OPN) is increased in patients with AS and to investigate its relationship to inflammatory disease activity and bone remodelling process. Methods. This cross-sectional study included 30 patients with AS and 23 age- and sex-matched healthy controls. We assessed clinical characteristics and laboratory parameters including the ESR, CRP, lipid profiles, the Bath AS disease activity index (BASDAI) and the Bath AS radiographic index (BASRI). To evaluate bone metabolism, we tested ALP, OCN and C-telopeptide of type I collagen (CTX-I). Plasma levels of OPN, TNF-α and IL-6 were measured by ELISA, and mRNA expression in peripheral blood mononuclear cells (PBMCs) was performed by RT-PCR. Changes in OPN level were also evaluated in eight patients after the treatment with a TNF-α blocker. Results. Patients with AS had significantly higher plasma OPN, TNF-α and IL-6 levels and more mRNA expression than healthy controls. Plasma OPN levels were correlated with serum ALP, OCN and CTX-I levels, but not with ESR, CRP, lipid profiles, BASDAI or BASRI. Treatment with a TNF-α blocker did not alter OPN levels, although it reduced the disease activity. Conclusions. Patients with AS had higher levels of OPN compared with controls. The plasma OPN level was correlated with serum ALP, OCN and CTX-I levels, but not with disease activity in AS. OPN might be involved in bone remodelling rather than in inflammation in AS.",
author = "Choi, {S. T.} and Kim, {J. H.} and Kang, {E. J.} and Lee, {S. W.} and Park, {M. C.} and YongBeom Park and Lee, {S. K.}",
year = "2008",
month = "11",
day = "28",
doi = "10.1093/rheumatology/ken385",
language = "English",
volume = "47",
pages = "1775--1779",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "12",

}

Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. / Choi, S. T.; Kim, J. H.; Kang, E. J.; Lee, S. W.; Park, M. C.; Park, YongBeom; Lee, S. K.

In: Rheumatology, Vol. 47, No. 12, 28.11.2008, p. 1775-1779.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis

AU - Choi, S. T.

AU - Kim, J. H.

AU - Kang, E. J.

AU - Lee, S. W.

AU - Park, M. C.

AU - Park, YongBeom

AU - Lee, S. K.

PY - 2008/11/28

Y1 - 2008/11/28

N2 - Objectives. To determine whether osteopontin (OPN) is increased in patients with AS and to investigate its relationship to inflammatory disease activity and bone remodelling process. Methods. This cross-sectional study included 30 patients with AS and 23 age- and sex-matched healthy controls. We assessed clinical characteristics and laboratory parameters including the ESR, CRP, lipid profiles, the Bath AS disease activity index (BASDAI) and the Bath AS radiographic index (BASRI). To evaluate bone metabolism, we tested ALP, OCN and C-telopeptide of type I collagen (CTX-I). Plasma levels of OPN, TNF-α and IL-6 were measured by ELISA, and mRNA expression in peripheral blood mononuclear cells (PBMCs) was performed by RT-PCR. Changes in OPN level were also evaluated in eight patients after the treatment with a TNF-α blocker. Results. Patients with AS had significantly higher plasma OPN, TNF-α and IL-6 levels and more mRNA expression than healthy controls. Plasma OPN levels were correlated with serum ALP, OCN and CTX-I levels, but not with ESR, CRP, lipid profiles, BASDAI or BASRI. Treatment with a TNF-α blocker did not alter OPN levels, although it reduced the disease activity. Conclusions. Patients with AS had higher levels of OPN compared with controls. The plasma OPN level was correlated with serum ALP, OCN and CTX-I levels, but not with disease activity in AS. OPN might be involved in bone remodelling rather than in inflammation in AS.

AB - Objectives. To determine whether osteopontin (OPN) is increased in patients with AS and to investigate its relationship to inflammatory disease activity and bone remodelling process. Methods. This cross-sectional study included 30 patients with AS and 23 age- and sex-matched healthy controls. We assessed clinical characteristics and laboratory parameters including the ESR, CRP, lipid profiles, the Bath AS disease activity index (BASDAI) and the Bath AS radiographic index (BASRI). To evaluate bone metabolism, we tested ALP, OCN and C-telopeptide of type I collagen (CTX-I). Plasma levels of OPN, TNF-α and IL-6 were measured by ELISA, and mRNA expression in peripheral blood mononuclear cells (PBMCs) was performed by RT-PCR. Changes in OPN level were also evaluated in eight patients after the treatment with a TNF-α blocker. Results. Patients with AS had significantly higher plasma OPN, TNF-α and IL-6 levels and more mRNA expression than healthy controls. Plasma OPN levels were correlated with serum ALP, OCN and CTX-I levels, but not with ESR, CRP, lipid profiles, BASDAI or BASRI. Treatment with a TNF-α blocker did not alter OPN levels, although it reduced the disease activity. Conclusions. Patients with AS had higher levels of OPN compared with controls. The plasma OPN level was correlated with serum ALP, OCN and CTX-I levels, but not with disease activity in AS. OPN might be involved in bone remodelling rather than in inflammation in AS.

UR - http://www.scopus.com/inward/record.url?scp=56649122122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56649122122&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/ken385

DO - 10.1093/rheumatology/ken385

M3 - Article

VL - 47

SP - 1775

EP - 1779

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 12

ER -